267 related articles for article (PubMed ID: 24395436)
1. Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer.
Levinsen M; Rotevatn EØ; Rosthøj S; Nersting J; Abrahamsson J; Appell ML; Bergan S; Bechensteen AG; Harila-Saari A; Heyman M; Jonsson OG; Maxild JB; Niemi M; Söderhäll S; Schmiegelow K;
Pediatr Blood Cancer; 2014 May; 61(5):797-802. PubMed ID: 24395436
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K; Al-Modhwahi I; Andersen MK; Behrendtz M; Forestier E; Hasle H; Heyman M; Kristinsson J; Nersting J; Nygaard R; Svendsen AL; Vettenranta K; Weinshilboum R;
Blood; 2009 Jun; 113(24):6077-84. PubMed ID: 19224761
[TBL] [Abstract][Full Text] [Related]
3. The circadian schedule for childhood acute lymphoblastic leukemia maintenance therapy does not influence event-free survival in the NOPHO ALL92 protocol.
Clemmensen KK; Christensen RH; Shabaneh DN; Harila-Saari A; Heyman M; Jonsson OG; Wesenberg F; Rosthøj S; Schmiegelow K;
Pediatr Blood Cancer; 2014 Apr; 61(4):653-8. PubMed ID: 24265159
[TBL] [Abstract][Full Text] [Related]
4. No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
Nielsen SN; Toksvang LN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Appell ML; Hjalgrim LL; Schmiegelow K
Cancer Chemother Pharmacol; 2021 Aug; 88(2):271-279. PubMed ID: 33928426
[TBL] [Abstract][Full Text] [Related]
5. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K; Forestier E; Kristinsson J; Söderhäll S; Vettenranta K; Weinshilboum R; Wesenberg F;
Leukemia; 2009 Mar; 23(3):557-64. PubMed ID: 18987654
[TBL] [Abstract][Full Text] [Related]
6. Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K; Heyman M; Kristinsson J; Mogensen UB; Rosthøj S; Vettenranta K; Wesenberg F; Saarinen-Pihkala U;
J Pediatr Hematol Oncol; 2009 Jun; 31(6):385-92. PubMed ID: 19648786
[TBL] [Abstract][Full Text] [Related]
7. Thiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: the Polish multicenter analysis.
Peregud-Pogorzelski J; Tetera-Rudnicka E; Kurzawski M; Brodkiewicz A; Adrianowska N; Mlynarski W; Januszkiewicz D; Drozdzik M
Pediatr Blood Cancer; 2011 Oct; 57(4):578-82. PubMed ID: 21319286
[TBL] [Abstract][Full Text] [Related]
8. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K
Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948
[TBL] [Abstract][Full Text] [Related]
9. Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study.
Frandsen TL; Abrahamsson J; Lausen B; Vettenranta K; Heyman M; Behrentz M; Castor A; Wehner PS; Frost BM; Andersen EW; Schmiegelow K
Br J Haematol; 2011 Oct; 155(2):244-7. PubMed ID: 21848519
[TBL] [Abstract][Full Text] [Related]
10. Analysis of thiopurine S-methyltransferase polymorphism in the population of Serbia and Montenegro and mercaptopurine therapy tolerance in childhood acute lymphoblastic leukemia.
Dokmanovic L; Urosevic J; Janic D; Jovanovic N; Petrucev B; Tosic N; Pavlovic S
Ther Drug Monit; 2006 Dec; 28(6):800-6. PubMed ID: 17164697
[TBL] [Abstract][Full Text] [Related]
11. Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics.
Lennard L; Cartwright CS; Wade R; Vora A
Br J Haematol; 2015 Apr; 169(2):228-40. PubMed ID: 25441457
[TBL] [Abstract][Full Text] [Related]
12. Role of TPMT and ITPA variants in mercaptopurine disposition.
Gerbek T; Ebbesen M; Nersting J; Frandsen TL; Appell ML; Schmiegelow K
Cancer Chemother Pharmacol; 2018 Mar; 81(3):579-586. PubMed ID: 29387964
[TBL] [Abstract][Full Text] [Related]
13. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia.
Stanulla M; Schaeffeler E; Flohr T; Cario G; Schrauder A; Zimmermann M; Welte K; Ludwig WD; Bartram CR; Zanger UM; Eichelbaum M; Schrappe M; Schwab M
JAMA; 2005 Mar; 293(12):1485-9. PubMed ID: 15784872
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia.
Hawwa AF; Collier PS; Millership JS; McCarthy A; Dempsey S; Cairns C; McElnay JC
Br J Clin Pharmacol; 2008 Dec; 66(6):826-37. PubMed ID: 18823306
[TBL] [Abstract][Full Text] [Related]
15. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
[TBL] [Abstract][Full Text] [Related]
16. Children with low-risk acute lymphoblastic leukemia are at highest risk of second cancers.
Nielsen SN; Eriksson F; Rosthoej S; Andersen MK; Forestier E; Hasle H; Hjalgrim LL; Aasberg A; Abrahamsson J; Heyman M; Jónsson ÓG; Pruunsild K; Vaitkeviciené GE; Vettenranta K; Schmiegelow K
Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28500740
[TBL] [Abstract][Full Text] [Related]
17. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia.
Schmiegelow K; Forestier E; Hellebostad M; Heyman M; Kristinsson J; Söderhäll S; Taskinen M;
Leukemia; 2010 Feb; 24(2):345-54. PubMed ID: 20010622
[TBL] [Abstract][Full Text] [Related]
18. Thiopurine S-methyltransferase phenotype-genotype correlation in children with acute lymphoblastic leukemia.
Chrzanowska M; Kuehn M; Januszkiewicz-Lewandowska D; Kurzawski M; Droździk M
Acta Pol Pharm; 2012; 69(3):405-10. PubMed ID: 22594254
[TBL] [Abstract][Full Text] [Related]
19. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia.
Schmiegelow K; Björk O; Glomstein A; Gustafsson G; Keiding N; Kristinsson J; Mäkipernaa A; Rosthøj S; Szumlanski C; Sørensen TM; Weinshilboum R
J Clin Oncol; 2003 Apr; 21(7):1332-9. PubMed ID: 12663723
[TBL] [Abstract][Full Text] [Related]
20. Thiopurine S-methyltransferase gene polymorphism and 6-mercaptopurine dose intensity in Indian children with acute lymphoblastic leukemia.
Kapoor G; Sinha R; Naithani R; Chandgothia M
Leuk Res; 2010 Aug; 34(8):1023-6. PubMed ID: 20153897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]